Parabilis Medicines initiates dose-ranging clinical study of zolucatetide in familial adenomatous polyposis

PBLS•2026-10-14

Parabilis Medicines initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis and plans to disclose additional Phase 1/2 trial data in the first quarter of 2027.

1. Study update

Parabilis Medicines initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis. The company plans to disclose additional data from its Phase 1/2 trial in the first quarter of 2027.

Parabilis Medicines initiates dose-ranging clinical study of zolucatetide in familial adenomatous polyposis

1. Study update

Related News

Kinder Morgan schedules third-quarter 2026 earnings webcast and conference call

Large cross-border deals in India's financial sector this year

Occidental Petroleum target price raised to $73 from $67

MNTN partners with Tealium to bring first-party CDP audiences into CTV ad targeting

Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead